Head-to-head evidence
lixisenatide vs XW014
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
lixisenatide · Adlyxin / Lyxumia
Marketed by Sanofi
NCT00707031 · Phase 3 · completed
The 639 participants were randomly assigned to lixisenatide or active treatment with exenatide, but the study was not blinded. The primary HbA1c comparison met its prespecified non-inferiority criterion, with a between-group difference of 0.17 percentage points and a 95% confidence interval of 0.033 to 0.297, but HbA1c is a surrogate endpoint rather than a hard clinical outcome.
Next expected readout: June 2027 · NCT07173712 (registry estimate)
XW014
Developed by Sciwind Biosciences
NCT05579314 · Phase 1 · completed
This is a randomized, blinded, placebo-controlled trial, but its primary endpoints are adverse events and routine safety measurements rather than a diabetes outcome such as blood sugar control, and no results have been posted yet.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: lixisenatide's landscape · XW014's landscape